Strategic Investment Solutions, Inc. /Il Lineage Cell Therapeutics, Inc. Transaction History
Strategic Investment Solutions, Inc. /Il
- $576 Billion
- Q4 2023
A detailed history of Strategic Investment Solutions, Inc. /Il transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Strategic Investment Solutions, Inc. /Il holds 44 shares of LCTX stock, worth $44. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44Holding current value
$44% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
126Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$42.5 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$8.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.37MShares$8.54 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$6.38 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$5.07 Million2.61% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $173M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...